Octreotide and lanreotide are the two long-established somatostatin analogs, and clinicians routinely weigh one against the other. Both mimic the body's natural hormone "off switch" to suppress growth hormone and other secretions, both are used for acromegaly and neuroendocrine tumors, and both are given as long-acting monthly injections. The practical differences are mostly in formulation and delivery rather than in what they fundamentally do.
At a glance
| Octreotide | Lanreotide | |
|---|---|---|
| Drug class | Somatostatin analog | Somatostatin analog |
| Brand names | Sandostatin, Sandostatin LAR | Somatuline Depot / Autogel |
| Main receptor | SSTR2 (and SSTR5) | SSTR2 (mainly) |
| Approved uses | Acromegaly, carcinoid syndrome, VIPoma, variceal bleeding | Acromegaly, gastroenteropancreatic neuroendocrine tumors |
| Long-acting form | Intramuscular depot (needs reconstitution) | Prefilled deep subcutaneous gel |
| Self-administration | LAR usually given by a professional | Autogel can be given at home by a trained caregiver |
| Landmark tumor trial | PROMID (midgut NETs) | CLARINET (enteropancreatic NETs) |
| Shared risks | Gallstones, GI effects, blood-sugar changes | Gallstones, GI effects, blood-sugar changes |
The bottom line
For most purposes octreotide and lanreotide are clinically interchangeable somatostatin analogs with overlapping uses and a shared side-effect profile dominated by gallstones and gastrointestinal effects. The choice often comes down to practicalities: lanreotide's prefilled deep-subcutaneous autogel can be more convenient and is easier to give outside a clinic, while octreotide has a short-acting form useful for testing tolerance and a broader set of labeled indications. Both are FDA-approved, prescription-only medicines used under specialist care.
Frequently asked questions
Is octreotide or lanreotide better?
Neither is clearly superior for most uses — they are closely related somatostatin analogs with similar effectiveness and side effects. Lanreotide's prefilled subcutaneous autogel is often more convenient, while octreotide has a short-acting form and a broader set of approved indications. The choice is individualized.
Can you switch between octreotide and lanreotide?
Switching between the two somatostatin analogs is done in clinical practice, but only under specialist supervision, since dose equivalence and individual response vary. This is a decision for the treating physician, not a self-adjustment.
What is the main difference between octreotide and lanreotide?
The biggest practical difference is delivery: octreotide's long-acting form is an intramuscular depot that needs reconstitution, while lanreotide comes as a prefilled deep-subcutaneous gel that can be given at home by a trained caregiver. Their mechanisms are very similar.
Are both octreotide and lanreotide FDA-approved?
Yes. Both are FDA-approved, prescription-only somatostatin analogs. Octreotide is approved for acromegaly, carcinoid syndrome, and VIPomas; lanreotide is approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2003. Peer-reviewed study
- Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm. 1989. Peer-reviewed study
- Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018. Peer-reviewed study
- Yang LP, Keating GM. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2010. Peer-reviewed study
- Castinetti F, Saveanu A, Morange I, et al. Lanreotide for the treatment of acromegaly. Adv Ther. 2009. Peer-reviewed study
- Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019. Peer-reviewed study
- Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014. Peer-reviewed study
- Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021. Peer-reviewed study
- Burness CB, Dhillon S, Keam SJ. Lanreotide autogel: a review of its use in the treatment of patients with acromegaly. Drugs. 2014. Peer-reviewed study